New treatment options and improved strategies for Lysosomal Storage Disorders (LSDs) diagnosis on dried blood spot (DBS) have led to the development of several pilot newborn screening programs.
Development of a fast LC-MS/MS protocol for combined measurement of six LSDs on dried blood spot in a newborn screening program 
Introduction
Lysosomal Storage Disorders (LSDs) are a group of more than 50 diseases sharing an impairment of lysosomal function. Over recent years, many of these conditions, which can be more successfully treated if diagnosed early, have been added to newborn screening panels as pilot projects [1] [2] [3] .
Since 2001, approaches for identifying LSD patients have been developed in research settings. Chamoles and colleagues described a fluorometric assay for diagnosing LSDs based on the use of dried blood spots (DBS) [4] [5] [6] [7] . Subsequently, Gelb and colleagues provided appropriate substrates and isotopically-labelled internal standards for performing multiple enzymatic assays by LC-MS/MS on DBS [8] . Currently, LC-MS/MS is the most commonly used technique for identifying LSDs during the neonatal period before clinical symptoms appear [2, 3, 9] .
In 2009, there was a significant breakthrough when a specific LC configuration was devised [10] for skipping the purification steps that were required before instrumental measurement in the original protocol. This configuration led to a more routine application of the method as the relatively short analytical measurement time (around 4 min, injection-to-injection), meant that it was possible to achieve higher sample throughputs. Moreover, the protocol relied on a single high-pressure binary LC pump and switching valve, [11] . This was possible thanks to some modifications on the chromatographic run which made the related IDUA IS and IDUA enzymatic product measurable.
Many protocols for lysosomal enzyme activation and measurement have been developed to allow the simultaneous detection of several enzymes on one or two DBS punches [12] [13] [14] [15] .
To ensure complete substrate digestion all the previously described protocols require long incubation times (at least 16-22 hours). However, this study demonstrates that more accurate product quantification could be achieved when the enzymatic reaction is still in its linearity window where product formation yield is directly proportional to incubation time.
Shortening incubation times makes large scale newborn screening more affordable and considerably reduces times for recall, diagnosis and therapeutic intervention in the case of severe neonatal onset forms for which very early treatment contributes to better outcomes [16] .
Material and methods

Chemicals and reagents
Substrate-Internal standard mixtures were obtained from the Centre for Disease Control and Prevention (CDC, Atlanta, Georgia).
Methanol, Isopropanol (LC-MS grade) and Formic acid (purity 98-100%) were purchased from Sigma-Aldrich (Riedel de Haën, Germany). Acetonitrile (LC-MS grade) and water (LC-MS grade) were procured from Biosolve Chemicals, (Valkensward, The Netherlands). In vitro diagnostic Whatman 903 ® grade blood spot cards were purchased from Whatman (Dassel, Germany). All the chemicals and reagents were used as commercially supplied without further purification.
Assay cocktail preparation
Each vial containing substrate-IS mixture was dissolved in methanol following the protocol developed by Spacil et al. [12] . A 1 mL aliquot from each vial was mixed together, dried under nitrogen flow and hydrated in 10 mL of 6-plex reaction buffer, prepared according to the procedure reported by Elliott et al. [17] .
Sample preparation
A 3.2 mm diameter disc, equivalent to approximately 3.4 L and 2.8 L of whole blood for newborns and adults respectively, was punched out directly into a 96-well plate. Samples were extracted and incubated in 30 L of cocktail buffer at 37 • C; different incubation times up to 12 h were tested. Four samples were prepared and analysed at each time point (2, 4, 6, 8, 10 and 12 h). After incubation, enzymatic reactions were quenched by 250 L of methanol + 0.1% formic acid and the plate was centrifuged at 2500 g for 5 min. The supernatant was transferred to a new 96-well plate and a 2 L sample was injected into the LC-MS/MS system through the autosampler kept at 8 • C.
Mass spectrometry and HPLC parameters
All measurements were performed using an LCMS-8050 TripleQuad Mass Spectrometer (Shimadzu, Japan) equipped with an ESI source and working in MRM mode. System control and data analysis were performed by LabSolutions software, version 5.65. MRM transitions for each compound were optimized by flow injection and are listed in Supplementary Information (Table S1) .
Other operating parameters were as follows: The HPLC system (Shimadzu, Japan) consisted of a Degassing Unit DGU-20A5R, controller CBM-20 A, two pump modules Nexera X2 LC-30AD, autosampler Nexera X2 SIL-30AC and column oven CTO-20AC equipped with a six-port valve. The LC modules were plumbed as shown in Fig. 1 .
Trapping and elution procedures were performed, as a modification of the described protocol [12] with a perfusion column POROS R1/20 2 × 30 mm (Applied Biosystems, FosterCity, CA, USA). For the chromatographic elution different columns were tested, including a Synergi Fusion RP-80 2 × 50 mm, 4 m (Phenomenex, Torrance USA), a ShimPack XR-ODS column 2 × 50 mm, 2.2 m (Shimadzu, Japan), and a Zorbax SB-CN 2,1 × 50 mm, 5 m (Agilent, Italy). The Zorbax SB-CN was chosen for routine use. The temperature of the column oven was set at 45 • C.
Pump A module was fed by an aqueous solution of 0.05% formic acid containing 10 mmol/L of ammonium formate while pump B module was fed by a mixture of acetonitrile-methanol-isopropanol (50:25:25, v/v/v) containing formic acid at 0.1%.
The entire workflow was programmed in three steps managed by the switching valve: sample loading and clean-up (1 min); analyte elution (2.5 min); for the final columns reconditioning (1 min) ( Table 1) .
In the first step, the injected sample is moved to the trapping column with 1.6 mL/min of eluent A for the cleanup. After 1 min, the valve is switched, and both the eluents A and B flows are merged for providing, after a 0.5 min-delay at 0%, a gradient of 50% eluent B moving to 100% in 2.0 min at a total flow rate of 400 L/min over the trapping and eluting columns now connected in series. With the analytes moved from the trapping column to the elution column, the valve is switched back to disconnect the two pumps and enable both the completion of chromatographic separation of the analytes with the full solvent B at 400 L/min over the chromatographic column, and the simultaneous reconditioning of the trapping column for the following injection. This last step lasts 1 min for a total run of 4.5 min.
Calculation of enzyme activity
Enzyme activity was reported as mol/L/h and calculated by using the following formula: V dbs = 3.4 or 2.8 L of whole blood contained into a 3.2 mm punch for newborn and adults, respectively 4h = incubation time Table 2 Reference value of LSD enzyme activity in newborn and adult population.
CUT OFF (mol/L/h) ENZYME NEWBORN (n = 1000)
Interday and intraday variability
Imprecision was determined in six replicates of four CDC control samples on the same day (intra-day imprecision) and duplicates for 5 times over a period of one week (inter-day imprecision). The imprecisions of the assay were expressed as a percentage coefficient of variation (CV%).
Cutoff determination
Reference values for the six lysosomal enzymes were determined both for newborn and adults by processing DBS of 1000 randomly chosen newborns and 200 adults. Quality controls provided by CDC and true positive samples were analysed to test the performance of the method and its ability to distinguish healthy individuals from affected individuals.
The lower limit of normal was set at the level of the 0.2nd percentile (Table 2) 
Results and discussion
Enzyme reaction parameters
Compared to similar studies, we totally revised the sample preparation process including the incubation time which is pivotal for a timely diagnosis. Long incubation times are often used to allow complete substrate digestion. However, this means that the calculated time-based enzyme activity may be underestimated after the reaction plateau is reached. A short assay time should lead to a more accurate product quantification since the reaction is still in the linear range.
Several incubation times of up to 12 h were tested for the six enzymatic reactions. The relationship between product yield and time was different for the six enzymes but commonly linear up to 6 h (Fig. 2) .
Within the time window of linear product accumulation, we chose an incubation time of 4 h because this proved long enough to produce a good signal of products and is short enough to be incorporated into a routine lab procedure. An incubation time of less than 4 h would risk compromising accuracy and an incubation time of more than 4 h would be incompatible with the time demands and routines of many laboratories."
This shortened sample preparation time satisfies the need for a more rapid analytical strategy which leads to faster diagnoses meaning that ERT can be introduced earlier and patient outcomes improved [16] .
DBS from healthy newborns and adults were analysed for cutoff determination and the method was validated by means of both CDC controls and true positive samples. Although, it is often very difficult to find sufficient numbers of DBS from true newborn posi- tive patients, we were able to test the assay effectiveness on 8 truly affected patients of whom 4 were newborns (1 Pompe, 2 Fabry, 1 MPS I) and 4 adults (1 Pompe, 2 Gaucher and 1 Krabbe). Since no patient with Niemann-Pick A/B disease was available, the assay was tested on CDC samples. All positive samples were correctly identified.
MS/MS conditions and LC configuration
In 2009 a first approach for a five LSD enzyme assay based on an on-line cleanup followed by chromatographic separation was developed in order to simplify and speed up sample preparation [10] . Subsequently a multiplex assay was implemented by adding IDUA measurement to the other five enzymes [11] .
In the new protocol described in this work, specific mass spectrometric parameters have been slightly modified, while LC configuration and optimization have been profoundly revised. This was necessary because of discrepancies concerning the accuracy of IDUA results after running several thousands of samples. After checking all the steps of the protocol, concerns arose about the peak shape of both the IDUA IS and IDUA product. Their peak shapes denoted as the signals were significantly distorted by residual matrix components supposedly eluting at the same retention time (RT). IDUA IS is a homologous compound of the investigated IDUA product and not an isotopologue. It is likely that some minor Fig. 3 . Extracted ion chromatograms related to the six products and their relative internal standards by running a CDC control sample. Chromatograms of ABG and GALC product result in two peaks. The first peak (ghost) is due to the product generated by in-source breakdown of substrate. While the RT of the ghost peak is the same as the substrate, the RT of the second peak corresponds to the product of the enzymatic reaction. matrix components released by the trapping column at the valve switching were making the ion-suppression impact slightly different on both analyte and internal standard.
To address this problem without elongating the running time, plumbing supporting the previous protocol was redesigned. The layout shown in Fig. 1 and the LC operating parameters (Table 1) provided a gradient elution at the time the valve was switched for a shifted release of the analytes from the trapping column. With this shift the ion-suppression impact mitigated and was similar for both the IDUA IS and the IDUA product. On the other side, eluting solvent B composition was reconsidered in order, to run the entire chromatographic process in less than 4.5 min, and to guarantee the cleanliness of both trapping and eluting columns, injection after injection. The eluting column was chosen to permit large-scale use.
For the chromatographic separation different columns were tested, including a Synergi Fusion RP-80 2 × 50 mm, 4 m (Phenomenex, Torrance USA), a ShimPack XR-ODS column 2 × 50 mm, 2.2 m (Shimadzu, Japan), and a Zorbax SB-CN 2,1 × 50 mm 5 m (Agilent, Italy). Besides, different organic solvent mixtures of acetonitrile and methanol, with or without isopropanol, were tested in order to evaluate the most appropriate composition of mobile phase B. Experimental data showed that a concentration of acetonitrile higher than 50% was not suitable since it extended the chromatographic run up to six minutes. A mixture of acetonitrile/ methanol/ isopropanol in the following ratio 50:25:25 (v/v/v) provided the best results in terms of chromatographic separation, robustness and short run time.
In terms of efficiency and resolution associated with high longterm robustness the Zorbax SB-CN column performed better than the other tested columns. A representative chromatogram is shown in Fig. 3 .
The final choice of the Zorbax SB-CN column instead of the previously used Synergi Fusion column, together with the aforementioned organic mixture for mobile phase B and the new plumbing led to an efficient and rapid chromatographic separation while maintaining a low pressure in the chromatographic plumbing.
This new configuration retained the advantages of a fast sample injection for a direct enzyme activity measurement without any other pretreatment. 
Method validation
The results for intra-day and inter-day imprecision (Table 3 ) were acceptable considering many factors contributing to variability, included matrix inhomogeneity. The intra-day and inter-day imprecision studies were less than 20% CVs for all 6 enzyme activities.
Conclusions
At present enzymatic activity assays performed on DBS, for newborn screening purposes or for confirming a clinical diagnosis, have an incubation time of at least 16 h. This study demonstrates that this time can be safely reduced to permit greater workloads and faster response times. We developed a protocol with a 4 h-incubation time.
The major concern regarding an enzyme activity assay with a short time is that the product formation may be insufficient to allow a clear distinction between healthy and affected individuals. However, this protocol was extensively tested not only on CDC but also on true positive samples to confirm that the four hour time interval, though short, is sufficient to convert the substrate into a quantifiable product when supported by the described LC-MS/MS measurement setting.
A fast diagnosis of severe neonatal-onset forms of LSDs is essential for effective pre-symptomatic intervention. A rapid screening procedure can reduce recall times for newborns who stand to benefit from the prompt introduction of treatment. The shorter incubation time adopted in our protocol reduces the time needed to make a diagnosis and introduce treatment by two days.
Any analytical method devised for clinical application must satisfy requirements of sensitivity, accuracy and precision as well as taking into consideration the reality of routine lab testing, which demands speed and robustness. The concept of robustness is often a little vague, but can be defined as the capacity of an analytical method to process a significant number of samples without compromising accuracy or sensitivity. In an LC-MS or LC-MS/MS system there are two potentially weak links; the ionization source and the chromatographic system. If chromatographic columns are not properly flushed, residues of the previous matrix may remain and contaminate the next sample injected. Residues that accumulate in an unexpected way generate unpredictable effects of ion suppression of the targeted components An optimized method must be conducted in a time frame compatible with a large-scale routine.
As outlined above, testing in our laboratory proved that the method we describe in this paper fulfils requirements of accuracy, sensitivity, precision, speed and robustness over a very large scale for three different instrumental settings.
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